Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited,
with the currently approved all‐oral regimens requiring 24‐week treatment and the addition …

Importance Hepatitis C virus (HCV) infects more than 185 million individuals worldwide.
Twenty percent of patients chronically infected with HCV progress to cirrhosis. New, simpler …

Background In phase 2 studies, treatment with the all-oral combination of the nucleotide
polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir resulted in high rates of …

Therapy for hepatitis C is undergoing a revolution. Several new drugs against the hepatitis C
virus (HCV) have reached the market and many others, including direct-acting antivirals and …

The rapidly expanding Zika virus (ZIKV) epidemic has affected thousands of individuals with
severe cases causing Guillain-Barré syndrome, congenital malformations, and …

Cirrhosis results from progressive fibrosis and is the final outcome of all chronic liver
disease. It is among the ten leading causes of death in United States. Cirrhosis can result in …

Background & Aims Interferon alfa–based regimens used to treat recurrent hepatitis C virus
(HCV) infection after liver transplantation are poorly tolerated, associated with generally …

Hepatitis C virus (HCV) is the most common cause of mixed cryoglobulinemia syndrome
(MCS). The efficacy and safety of all‐oral direct‐acting antiviral (DAA) therapy in HCV …

Background There is a high medical need for an interferon-free, all-oral, short-duration
therapy for hepatitis C virus (HCV) that is highly effective across diverse patient populations …

Appendices published as WHO/HIV/2014.22, WHO/HIV/2014.24, WHO/HIV/2014.28,
WHO/HIV/2014.29, WHO/HIV/2014.30, WHO/HIV/2014.33, WHO/HIV/2014.34 …